An Open-Label, Randomized, Multicenter, Phase II, Non Comparative, Exploratory Study on Neoadjuvant Treatment With Trastuzumab Plus Docetaxel Plus Bevacizumab According to Positon Emission Tomography (PET) Value Modification in Patients With Early Stage HER2 Positive Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 19 Mar 2018
At a glance
- Drugs Bevacizumab (Primary) ; Docetaxel; Trastuzumab
- Indications Early breast cancer
- Focus Therapeutic Use
- Acronyms AVATAXHER
- Sponsors Roche
- 15 Mar 2018 Status changed from active, no longer recruiting to completed.
- 22 Feb 2018 Planned End Date changed from 31 Jan 2018 to 28 Feb 2018.
- 22 Feb 2018 Planned primary completion date changed from 31 Jan 2018 to 28 Feb 2018.